ABSTRACT
Metformin, an antidiabetic drug, triggers anti-aging cellular responses. Aging is the principal risk factor for dementia, but previous observational studies of the diabetes drugs metformin vs. sulfonylureas have been mixed. We tested the hypotheses that metformin improves survival and reduces the risk of dementia, relative to the sulfonylureas, by emulating target trials in electronic health records of diabetic patients at an academic-centered healthcare system in the US and a wide-ranging group of primary care practices in the UK. To address metformin’s potentially dual influences on dementia risk—that it might reduce the hazard of death and put more people at risk of developing dementia while reducing the hazard of dementia by slowing biological aging, we used a competing risks approach and carefully grounded that within a causal inference emulated trial framework. To identify candidate biomarkers of metformin’s actions in the brain that might mediate reduced dementia risk, we conducted an in-vitro systems pharmacology evaluation of metformin and glyburide on differentiated human neural cells through differential gene expression. We named our multi-dimensional approach DRIAD-EHR (Drug Repurposing in Alzheimer’s Disease-Electronic Health Records). In intention-to-treat analyses, metformin was associated with a lower hazard of all-cause mortality than sulfonylureas in both cohorts. In competing risks analyses, there was also a lower cause-specific hazard of dementia onset among metformin initiators. In in-vitro studies, metformin reduced human neural cell expression of SPP1 and APOE, two secreted proteins that have been implicated in Alzheimer’s disease pathogenesis and whose levels can be quantified in the CSF. Together, our findings suggest that metformin might prevent dementia in patients without type II diabetes. In addition, our results inform the design of clinical trials of metformin in non-diabetics and suggest a pharmacodynamic CSF biomarker, SPP1, for metformin’s action in the brain.
Competing Interest Statement
B.T.H. is a member of the SAB and owns shares in Dewpoint. He also serves on an advisory panel for Biogen, and his laboratory has current research funding from AbbVie. His wife is an employee and shareholder of Novartis. R.A.B. serves on an advisory board for Biogen. M.W.A. is a consultant for Transposon Rx and receives research support from IFF.
Funding Statement
We thank the NIH R01 AG058063 (awarded to M.W.A), P30 AG062421 (awarded to B.T.H.), a CART grant (awarded to M.W.A.), an administrative supplement to U54 CA22508 (awarded to M.W.A.), IBM Research (awarded to R.E.W. and S.N.F.), the Abdul Latif Jameel Clinic for Machine Learning in Health grant (awarded to R.E.W. and S.N.F.), the UK Dementia Research Institute which receives its funding from UK DRI Ltd, funded by the UK Medical Research Council (awarded to I.T.), the Alzheimer's Society and Alzheimer's Research UK, support by the British Heart Foundation Centre for Research Excellence at Imperial College (awarded to I.T.), the Hellenic Foundation for Research and Innovation (HFRI) (awarded to I.T.), and the General Secretariat for Research and Technology (GSRT) (awarded to I.T.) for support.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Use of RPDR data for this study was approved by the institutional review board (IRB) of MGB. Use of CPRD data for this study was approved by the Independent Scientific Advisory Committee (ISAC) for Medicines and Healthcare products Regulatory Agency (MHRA) database research (protocol number: 19_065R).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵^ Contact author with Journal
Data Availability
US RPDR. Researchers can obtain an anonymized version of the study dataset from the authors upon request and completion of the MGB Health data use agreement for the use of RPDR data. This agreement ensures the privacy of MGB patients and compliance with US regulatory standards and has been approved by the MGB IRB. UK CPRD. According to the UK Data Protection Act, information governance restrictions (to protect patient confidentiality) prevent data sharing via public deposition. Therefore, CPRD data that support the findings of this study are not publicly available. Data extracts can be requested by applying to the Clinical Practice Research Datalink for data spanning the years 2000 to 2018 (https://www.cprd.com). The code to process the data is available from the authors upon request. Metformin/Glyburide RNA-seq. https://www.synapse.org/#!Synapse:syn22213067
